newsfilter
← Latest News
GlobeNewswire·

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 –